609 related articles for article (PubMed ID: 11976828)
1. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
2. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
3. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
[TBL] [Abstract][Full Text] [Related]
4. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
Hirota H; Gosky D; Berger NA; Chatterjee S
Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
[TBL] [Abstract][Full Text] [Related]
5. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
7. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
10. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
11. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
13. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
14. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Mainwaring MG; Rimsza LM; Chen SF; Gomez SP; Weeks FW; Reddy V; Lynch J; May WS; Kahn S; Moreb J; Leather H; Braylan R; Rowe TC; Fieniewicz KJ; Wingard JR
Leuk Lymphoma; 2002 May; 43(5):989-99. PubMed ID: 12148910
[TBL] [Abstract][Full Text] [Related]
17. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
19. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
Harker WG; Slade DL; Parr RL; Holguin MH
Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
[TBL] [Abstract][Full Text] [Related]
20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]